Evofem Biosciences, Inc.
OTC:EVFM
0.07 (USD) • At close November 17, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 18.218 | 16.837 | 8.244 | 0.446 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 |
| Cost of Revenue
| 8.293 | 4.415 | 4.055 | 0.468 | 0.905 | 0.262 | 0.244 | 0.069 | 0.058 | 0 | 0 | 0 |
| Gross Profit
| 9.925 | 12.422 | 4.189 | -0.022 | -0.905 | -0.262 | -0.244 | -0.069 | -0.058 | 0 | 0 | 0.1 |
| Gross Profit Ratio
| 0.545 | 0.738 | 0.508 | -0.049 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 2.462 | 25.032 | 33.129 | 17.05 | 22.23 | 43.415 | 3.946 | 6.579 | 34.41 | 5.175 | 11.448 | 3.249 |
| General & Administrative Expenses
| 14.95 | 27.563 | 24.709 | 30.085 | 30.512 | 34.227 | 6.099 | 5.464 | 7.639 | 4.416 | 2.975 | 2.592 |
| Selling & Marketing Expenses
| 11.664 | 43.951 | 113.152 | 56.467 | 10.123 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 25.31 | 71.514 | 137.861 | 86.552 | 30.512 | 34.227 | 6.099 | 5.464 | 7.639 | 4.416 | 2.975 | 2.592 |
| Other Expenses
| -2.628 | -2.087 | -4.732 | -2.082 | -19.99 | -0.145 | 0 | 0 | 0 | 0 | -0.047 | 0 |
| Operating Expenses
| 27.772 | 96.546 | 170.99 | 103.602 | 52.742 | 77.642 | 10.045 | 12.042 | 42.049 | 9.591 | 14.423 | 5.841 |
| Operating Income
| -17.847 | -84.124 | -166.801 | -103.624 | -52.742 | -77.642 | -10.045 | -12.042 | -42.049 | -9.591 | -14.423 | -5.741 |
| Operating Income Ratio
| -0.98 | -4.996 | -20.233 | -232.341 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -57.41 |
| Total Other Income Expenses Net
| 70.843 | 7.47 | -38.374 | -38.681 | -27.287 | -48.195 | 0.051 | -0.976 | -1.108 | -0.861 | -0.538 | -1.152 |
| Income Before Tax
| 52.996 | -76.654 | -205.175 | -142.305 | -80.029 | -125.71 | -9.993 | -13.019 | -43.157 | -10.819 | -15.016 | -7.828 |
| Income Before Tax Ratio
| 2.909 | -4.553 | -24.888 | -319.07 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -78.276 |
| Income Tax Expense
| 0.017 | 0.044 | 0.017 | 0.004 | 0.004 | 0.002 | 0.051 | -0.01 | -0.032 | 0.357 | 0.01 | 0.937 |
| Net Income
| 52.979 | -76.698 | -205.192 | -142.309 | -80.033 | -125.712 | -9.993 | -13.019 | -43.157 | -10.819 | -15.016 | -7.828 |
| Net Income Ratio
| 2.908 | -4.555 | -24.89 | -319.078 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -78.276 |
| EPS
| 10.36 | -163.19 | -2,931.31 | -3,557.72 | -4,001.65 | -10,763.01 | -9,563.11 | -10,618.76 | -35,461.83 | -8,904.72 | -12,736.43 | -6,639.2 |
| EPS Diluted
| 0.05 | -163.19 | -2,931.31 | -3,557.72 | -4,001.65 | -10,763.01 | -9,563.11 | -10,618.76 | -35,461.83 | -8,904.72 | -12,736.43 | -6,639.2 |
| EBITDA
| -16.066 | -93.596 | -133.144 | -66.856 | -44.987 | -29.592 | -9.948 | -11.983 | -42.023 | -9.584 | -14.396 | -5.616 |
| EBITDA Ratio
| -0.882 | -5.559 | -16.15 | -149.901 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -56.156 |